Following the recent U.S Food and Drug Administration (FDA) approval of the Prior Approval Supplement (PAS) for second-generation Andexxa, Portola Pharmaceuticals and Lonza started commercial supply of the recombinant coagulation factor from Lonza’s Porriño, Spain facility.   The production at Lonza Pharma & Biotech’s 10,000L mammalian facility in Porriño will be supplemented by additional large-scale capacity in Ibex Dedicate at Lonza’s Visp, Switzerland site when it comes on line in 2020...